Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies - PubMed (original) (raw)
Review
Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies
Paolo Fusar-Poli et al. J Clin Psychopharmacol. 2012 Apr.
Abstract
Background: Omega-3 fatty acids, in particular, eicosapentaenoic acid (EPA) have been suggested as augmentation strategies in the treatment of schizophrenia and related psychosis. Published results are conflicting, and the antipsychotic efficacy of such augmentation strategies is not well established.
Methods: Double-blind, randomized, placebo-controlled studies using purified or EPA-enriched oils in established schizophrenia were included in a meta-analysis. The effect size of EPA on psychotic symptoms was measured using Hedges' g. Publication bias was assessed with funnel plots and Egger's intercept. Heterogeneity was assessed with Q statistic and I index. Influence of moderators was assessed with meta-regression analyses in Comprehensive Meta-analysis Software version 2.
Results: The database included 167 schizophrenic subjects under the placebo arm (mean age, 37 [SD, 9.7] years; 37% females) matched with 168 schizophrenic subjects under the EPA arm (mean age, 37 [SD, 7.9] years; 36% females) (t tests P > 0.05). Meta-analysis showed no consistent significant effect for the EPA augmentation on psychotic symptoms (Hedges' g = 0.242; 95% confidence interval, 0.028-0.512, Z = 1.7531, P > 0.05). There were no significant effects for moderator variables such as age, sex, and EPA dose used in the trials. Heterogeneity across studies was small and statistically non significant (Q = 9.06; P = 0.170; I = 33.81).
Conclusions: Meta-analysis of randomized controlled trials on symptomatic outcome revealed no beneficial effect of EPA augmentation in established schizophrenia. However, no conclusion can be made for medium- to long-term effects of EPA in schizophrenia, in particular on relapse prevention in the early course of psychotic disorders.
Similar articles
- Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM. Emsley R, et al. Psychiatry Res. 2008 Dec 15;161(3):284-91. doi: 10.1016/j.psychres.2007.06.029. Epub 2008 Oct 29. Psychiatry Res. 2008. PMID: 18962989 Clinical Trial. - Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
Fusar-Poli P, Kempton MJ, Rosenheck RA. Fusar-Poli P, et al. Int Clin Psychopharmacol. 2013 Mar;28(2):57-66. doi: 10.1097/YIC.0b013e32835b091f. Int Clin Psychopharmacol. 2013. PMID: 23165366 Review. - Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Woods SW, et al. Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961. Arch Gen Psychiatry. 2005. PMID: 16143728 Review. - Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM, Smith L. Taylor DM, et al. Acta Psychiatr Scand. 2009 Jun;119(6):419-25. doi: 10.1111/j.1600-0447.2009.01367.x. Epub 2009 Feb 25. Acta Psychiatr Scand. 2009. PMID: 19245679 - Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Amminger GP, et al. Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192. Arch Gen Psychiatry. 2010. PMID: 20124114 Clinical Trial.
Cited by
- Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs.
Fond G, Mallet J, Urbach M, Benros ME, Berk M, Billeci M, Boyer L, Correll CU, Fornaro M, Kulkarni J, Leboyer M, Llorca PM, Misdrahi D, Rey R, Schürhoff F, Solmi M, Sommer IEC, Stahl SM, Pignon B, Berna F. Fond G, et al. BMJ Ment Health. 2023 Oct;26(1):e300771. doi: 10.1136/bmjment-2023-300771. BMJ Ment Health. 2023. PMID: 37852631 Free PMC article. - Immunological Biomarkers as Predictors of Treatment Response in Psychotic Disorders.
Orbe EB, Benros ME. Orbe EB, et al. J Pers Med. 2023 Sep 15;13(9):1382. doi: 10.3390/jpm13091382. J Pers Med. 2023. PMID: 37763150 Free PMC article. Review. - Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid.
Adrien V, Bosc N, Fumat H, Tessier C, Ferreri F, Mouchabac S, Tareste D, Nuss P. Adrien V, et al. Front Psychiatry. 2023 Feb 3;14:1089724. doi: 10.3389/fpsyt.2023.1089724. eCollection 2023. Front Psychiatry. 2023. PMID: 36816405 Free PMC article. - Inflammation and JNK's Role in Niacin-GPR109A Diminished Flushed Effect in Microglial and Neuronal Cells With Relevance to Schizophrenia.
Ansarey SH. Ansarey SH. Front Psychiatry. 2021 Nov 30;12:771144. doi: 10.3389/fpsyt.2021.771144. eCollection 2021. Front Psychiatry. 2021. PMID: 34916973 Free PMC article. Review. - Nutrition, nutritional deficiencies, and schizophrenia: An association worthy of constant reassessment.
Onaolapo OJ, Onaolapo AY. Onaolapo OJ, et al. World J Clin Cases. 2021 Oct 6;9(28):8295-8311. doi: 10.12998/wjcc.v9.i28.8295. World J Clin Cases. 2021. PMID: 34754840 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials